NASDAQ:DTIL Precision BioSciences Q2 2025 Earnings Report $4.61 -0.39 (-7.80%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$4.64 +0.03 (+0.65%) As of 09/12/2025 05:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Precision BioSciences EPS ResultsActual EPS-$2.13Consensus EPS -$0.09Beat/MissMissed by -$2.04One Year Ago EPSN/APrecision BioSciences Revenue ResultsActual Revenue$0.02 millionExpected Revenue$6.27 millionBeat/MissMissed by -$6.25 millionYoY Revenue GrowthN/APrecision BioSciences Announcement DetailsQuarterQ2 2025Date8/7/2025TimeBefore Market OpensConference Call DateThursday, August 7, 2025Conference Call Time12:30PM ETUpcoming EarningsPrecision BioSciences' Q3 2025 earnings is scheduled for Monday, November 3, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Precision BioSciences Earnings HeadlinesPrecision BioSciences Presents Data from the Phase 1 ELIMINATE-B Trial of PBGENE-HBV at the 6th International Coalition to Eliminate HBV Cure SymposiumSeptember 12 at 7:01 AM | businesswire.comPrecision BioSciences announces in vivo gene editing program patent from USPTOSeptember 8, 2025 | msn.comTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.September 13 at 2:00 AM | Porter & Company (Ad)Precision BioSciences Announces U.S. Patent Covering PBGENE-HBV for Chronic Hepatitis B and Updates Program StatusSeptember 8, 2025 | businesswire.comPrecision BioSciences Reports Promising Phase 1 Trial ResultsAugust 14, 2025 | theglobeandmail.comPrecision BioSciences Reports Significant Quarterly LossAugust 12, 2025 | theglobeandmail.comSee More Precision BioSciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Precision BioSciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Precision BioSciences and other key companies, straight to your email. Email Address About Precision BioSciencesPrecision BioSciences (NASDAQ:DTIL) is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors. Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area. The company completed a business combination with a special purpose acquisition company (SPAC) in 2021 and began trading on the Nasdaq under the ticker DTIL. Over its history, Precision BioSciences has focused on optimizing ARCUS for high specificity, efficiency and manufacturability, laying the groundwork for scalable gene editing solutions. Precision BioSciences is led by President and Chief Executive Officer Matt Kane, who has steered the company’s scientific and strategic initiatives since joining in 2014. Under his leadership, the company has established collaborations with academic institutions and biopharmaceutical partners to advance preclinical studies and clinical trials. With a focus on innovation and translational research, Precision BioSciences aims to bring next‐generation gene therapies from discovery through to regulatory approval and commercialization.View Precision BioSciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Celsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 EarningsWhy Broadcom's Q3 Earnings Were a Huge Win for AVGO BullsAffirm Crushes Earnings Expectations, Turns Bears into BelieversAmbarella's Earnings Prove Its Edge AI Strategy Is a WinnerWhat to Watch for From D-Wave Now That Earnings Are DoneDICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? Upcoming Earnings FedEx (9/18/2025)Micron Technology (9/23/2025)AutoZone (9/23/2025)Cintas (9/24/2025)Costco Wholesale (9/25/2025)Accenture (9/25/2025)NIKE (9/30/2025)PepsiCo (10/9/2025)BlackRock (10/10/2025)Fastenal (10/13/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
